# A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer

> **NCT00885963** · PHASE2 · TERMINATED · sponsor: **Cyclacel Pharmaceuticals, Inc.** · enrollment: 62 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** sapacitabine

## Key facts

- **NCT ID:** NCT00885963
- **Lead sponsor:** Cyclacel Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12-01
- **Primary completion:** 2013-08-13
- **Final completion:** 2013-12-23
- **Target enrollment:** 62 (ACTUAL)
- **Why stopped:** Limitation in financial resources.
- **Last updated:** 2021-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00885963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00885963, "A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00885963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*